Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma

References

• Adams J. (2004). The proteasome: A suitable antineoplastic target. Nat Rev Cancer, 4, 349–360.
   PubMed Web of Science ®Google Scholar
• Archer CR, Koomoa DL, Mitsunaga EM, Clerc J, Shimizu M, Kaiser M, Schellenberg B, Dudler R, Bachmann AS. (2010). Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma. Biochem Pharmacol, 80, 170–178.
   Google Scholar
• Bachmann AS. (2008). Proteasome inhibitors in pediatric cancer treatment. Hawaii Med J, 67, 247–249.
   PubMedGoogle Scholar
• Clerc J, Florea BI, Kraus M, Groll M, Huber R, Bachmann AS, Dudler R, Driessen C, Overkleeft HS, Kaiser M. (2009a). Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem, 10, 2638–2643.
   PubMed Web of Science ®Google Scholar
• Clerc J, Groll M, Illich DJ, Bachmann AS, Huber R, Schellenberg B, Dudler R, Kaiser M. (2009b). Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proc Natl Acad Sci USA, 106, 6507–6512.
   PubMed Web of Science ®Google Scholar
• Clerc J, Schellenberg B, Groll M, Bachmann AS, Huber R, Dudler R, Kaiser M. (2010). Convergent synthesis and biological evaluation of syringolin A and derivatives as eukaryotic 20S proteasome inhibitors. Eur J Org Chem, 21, 3991–4003.
   Google Scholar
• Clerc J, Li N, Krahn D, Groll M, Bachmann AS, Florea BI, Overkleeft HS, Kaiser M. (2011). The natural product hybrid of syringolin A and glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Chem Commun (Camb), 47, 385–387.
   PubMed Web of Science ®Google Scholar
• Coleman CS, Rocetes JP, Park DJ, Wallick CJ, Warn-Cramer BJ, Michel K, Dudler R, Bachmann AS. (2006). Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis. Cell Prolif, 39, 599–609.
   PubMed Web of Science ®Google Scholar
• Dai C, Stephenson CR. (2010). Total synthesis of syringolin A. Org Lett, 12, 3453–3455.
   PubMedGoogle Scholar
• Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. (2003). Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol, 31, 271–282.
   PubMed Web of Science ®Google Scholar
• Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, Lindow S, Kaiser M, Dudler R. (2008). A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature, 452, 755–758.
   PubMed Web of Science ®Google Scholar
• Hirano SS, Upper CD. (2000). Bacteria in the leaf ecosystem with emphasis on Pseudomonas syringae-a pathogen, ice nucleus, and epiphyte. Microbiol Mol Biol Rev, 64, 624–653.
   PubMed Web of Science ®Google Scholar
• Ibarra-Rivera TR, Opoku-Ansah J, Ambadi S, Bachmann AS, Pirrung MC. (2011). Syntheses and cytotoxicity of syringolin B-based proteasome inhibitors. Tetrahedron. (In Press).
   Web of Science ®Google Scholar
• Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. (2008). Molecular basis of bortezomib resistance: Proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 112, 2489–2499.
   PubMed Web of Science ®Google Scholar
• Oka M, Nishiyama Y, Ohta S, Kamei H, Konishi M, Miyaki T, Oki T, Kawaguchi H. (1988a). Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity. J Antibiot, 41, 1331–1337.
   PubMed Web of Science ®Google Scholar
• Oka M, Numata K, Nishiyama Y, Kamei H, Konishi M, Oki T, Kawaguchi H. (1988b). Chemical modification of the antitumor antibiotic glidobactin. J Antibiot, 41, 1812–1822.
   PubMed Web of Science ®Google Scholar
• Oka M, Ohkuma H, Kamei H, Konishi M, Oki T, Kawaguchi H. (1988c). Glidobactins D, E, F, G and H; minor components of the antitumor antibiotic glidobactin. J Antibiot, 41, 1906–1909.
   PubMed Web of Science ®Google Scholar
• Oka M, Yaginuma K, Numata K, Konishi M, Oki T, Kawaguchi H. (1988d). Glidobactins A, B and C, new antitumor antibiotics. II. Structure elucidation. J Antibiot, 41, 1338–1350.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Kuhn DJ. (2008). Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res, 14, 1649–1657.
   PubMed Web of Science ®Google Scholar
• Pirrung MC, Biswas G, Ibarra-Rivera TR. (2010). Total synthesis of syringolin A and B. Org Lett, 12, 2402–2405.
   PubMedGoogle Scholar
• Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R. (2010). Bortezomib-resistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia, 24, 1506–1512.
   PubMed Web of Science ®Google Scholar
• Shoji J, Hinoo H, Kato T, Hattori T, Hirooka K, Tawara K, Shiratori O, Terui Y. (1990). Isolation of cepafungins I, II and III from Pseudomonas species. J Antibiot, 43, 783–787.
   PubMed Web of Science ®Google Scholar
• Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. (2005). The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA, 102, 731–736.
   PubMed Web of Science ®Google Scholar
• Terui Y, Nishikawa J, Hinoo H, Kato T, Shoji J. (1990). Structures of cepafungins I, II and III. J Antibiot, 43, 788–795.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Dees EC, O’Neil B, Orlowski RZ. (2003). The proteasome as a target for cancer therapy. Clin Cancer Res, 9, 6316–6325.
   PubMed Web of Science ®Google Scholar